Physician profile
Laura W Meyer
NPI 1043227499
$15,408.08
in general payments reported to CMS, 2019-2025
57 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $1,623 · 2021: $2,318 · 2022: $2,555 · 2023: $2,577 · 2024: $2,540 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,378.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,320.55 | 2020-2025 | |
| Pfizer INC. | $1,667.25 | 2019-2025 | |
| Novo Nordisk INC | $1,561.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,550.21 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,314.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,099.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $691.02 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $684.85 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $326.84 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $318.37 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $298.70 | 2022 | |
| Lundbeck LLC | $272.83 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.42 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.60 | 2019-2023 | Ofev, Jardiance |
| Novartis Pharmaceuticals Corporation | $202.27 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.